Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Grapefruit Benefits

Beating The Radar: Getting A Jump On Storm Prediction
Satellite observation of cloud temperatures may be able to accurately predict severe thunderstorms up to 45 minutes earlier than relying on traditional radar alone, say researchers at the University of Wisconsin-Madison Space Science and Engineering Center.
generic viagra online
Opinion Pieces, Editorial Discuss Federal Needle Exchange Funding Ban
Summaries of two opinion pieces and an editorial related to the ban on the use of federal funding for needle exchange and recent congressional action appear below.
News of the day
Extracorporeal Shock Wave Therapy For The Treatment Of Chronic Pelvic Pain Syndrome In Males: A Randomised, Double-Blind, Placebo-Controlled Study
UroToday.com - At a glance one could assume that this study was solely empirical - on the contrary! Shock waves (SWs) seem to have a greater therapeutic potential than is assumed and understood today. Finally, the effect of SW cannot be explained by current models of thinking. The recently published SW model by Wess1 is a very promising and tremendous basic approach: SW could modify brain processes and pain storage patterns - both to be influenced therapeutically. We are going to follow these concepts by specific research investigating processes inside the brain during SW application. Possible reactions in the brain and changes under running Extracorporeal Shock Wave Treatment (ESWT) are presently the most promising approaches to understanding the working mechanisms of SW. We intend to apply SWs not only clinically, but also to enhance our knowledge by basic research about their therapeutic effects. The missing animal model for chronic pelvic pain syndrome (CPPS) does not contribute to simplifying the understanding of pathophysiological processes influenced by ESWT, in particular due to the fact that the knowledge about CPPS pathophysiology itself is very limited.
Health Insurance

Advancing Vaccine Against Valley Fever - UTSA Infectious Disease Researchers

Medical mycologists in The South Texas Center for Emerging Infectious Diseases (STCEID) and the Department of Biology at The University of Texas at San Antonio (UTSA) have significantly advanced the fight against San Joaquin Valley Fever, a respiratory infection of humans, commonly called Valley Fever, which is caused by the Coccidioides fungus. For the first time, the researchers have genetically engineered a live, attenuated vaccine that successfully protects mice against Valley Fever, known in scientific circles as coccidioidomycosis. A live, attenuated vaccine is used as a preventative treatment based upon creation of a mutated form of the pathogen that is no longer capable of causing disease. Coccidioides, a soil-dwelling fungus, is responsible for significantly increased numbers of respiratory infections among outdoor workers when compared to the general population. In addition, people with compromised T-cell immunity, the elderly and certain racial groups, such as African-Americans and Filipinos who live in the Southwestern United States, have an increased incidence of the infection"s symptoms, caused by the inhalation of Coccidioides spores. In approximately 40% of human Valley Fever cases, respiratory problems set in one to three weeks after inhalation. Although less than one percent of infected individuals experience severe symptoms, such as chronic-progressive pneumonia or meningitis, the incidence of reported primary pulmonary infection cases in Arizona and California is on the rise, having significantly increased in the last decade. STCEID researchers at UTSA and Wilford Hall Medical Center at San Antonio"s Lackland Air Force Base have long collaborated on Coccidioides studies in the hopes of developing a vaccine to better protect those who are exposed to it in the future. This most recent study has been funded by the National Institute of Allergy and Infectious Diseases, the California HealthCare Foundation and the Margaret Batts Tobin Foundation. "Respiratory infections caused by Coccidioides tend to escape the radar of most large pharmaceutical companies, because only about 100,000 cases are reported each year," said Garry Cole, professor of biology at UTSA and the study"s principal investigator. He adds, "But when I look at 100,000 cases, I see 100,000 faces looking back at me." Christi Fish University of Texas at San Antonio


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009